Table 2.
Bupropion N=406 |
Citalopram N=385 |
Desvenlafaxine N=16 |
Duloxetine N=139 |
Escitalopram N=581 |
Fluoxetine N=579 |
Paroxetine N=55 |
Sertraline N=1653 |
Venlafaxine N=132 |
Overall cohort N=3694 |
|
---|---|---|---|---|---|---|---|---|---|---|
Pregnancy Outcomes | ||||||||||
Neonatal/Fetal Death | 3 (0.7%) | 2 (0.5%) | 0 (0%) | 0 (0%) | 1 (0.2%) | 0 (0%) | 0 (0%) | 6 (0.3%) | 0 (0%) | 11 (0.3%) |
TTN * | 35 (8.6%) | 48 (12.5%) | 0 (0%) | 21 (15.1%) | 76 (13.0) | 83 (14.3%) | 9 (16.4%) | 172 (10.4%) | 24 (18.2%) | 437 (11.8%) |
Newborn Intubated | 5 (1.2%) | 12 (3.1%) | 0 (0%) | 6 (4.3%) | 15 (2.6%) | 18 (3.1%) | 2 (3.6%) | 30 (1.8%) | 4 (3.0%) | 84 (2.3%) |
Pulmonary Hypertension | 0 (0%) | 2 (0.5%) | 0 (0%) | 1 (0.7%) | 2 (0.3%) | 2 (0.4%) | 0 (0%) | 3 (0.2%) | 0 (0%) | 10 (0.3%) |
Seizures | 1 (0.2%) | 2 (0.5%) | 0 (0%) | 0 (0%) | 3 (0.5%) | 5 (0.9%) | 1 (1.8%) | 5 (0.3%) | 0 (0%) | 15 (0.4%) |
Jaundice | 63 (15.5%) | 55 (14.3%) | 3 (18.8%) | 21 (15.1%) | 90 (15.5%) | 91 (15.7%) | 6 (10.9%) | 228 (13.8%) | 18 (13.6%) | 548 (14.8%) |
Cardiac Malformations | 13 (3.2%) | 19 (4.9%) | 0 (0%) | 6 (4.3%) | 26 (4.5%) | 25 (4.3%) | 4 (7.3%) | 64 (3.9%) | 3 (2.3%) | 153 (4.1%) |
5 Min APGAR <7 | 50 (12.3%) | 56 (14.6%) | 3 (18.8%) | 22 (15.8%) | 66 (11.4%) | 99 (17.1%) | 9 (16.4%) | 213 (12.9%) | 20 (15.2%) | 504 (13.6%) |
Any Adaptation Syndrome * | 19 (4.7%) | 35 (9.1%) | 1 (6.2%) | 21 (15.1%) | 51 (8.8%) | 34 (5.9%) | 7 (12.7%) | 75 (4.5%) | 9 (6.8%) | 228 (6.2%) |
NICU Admission * | 91 (22.4%) | 105 (27.3%) | 3 (18.8%) | 55 (39.6%) | 172 (29.6%) | 162 (28.0%) | 16 (29.1%) | 384 (23.2%) | 33 (25.0%) | 943 (25.5%) |
Preterm Birth | 61 (15.0%) | 56 (14.6%) | 2 (12.5%) | 32 (23.0%) | 85 (14.6%) | 100 (17.3%) | 8 (14.6%) | 238 (14.3%) | 18 (13.6%) | 559 (15.1%) |
Data presented as n (% of with characteristic or outcome) in individual groups.
Statistically significant rate differences of outcome distribution between the drugs (p<0.05)
TTN= transient tachypnea of the newborn; NICU = neonatal intensive care unit